Ratiograstim er indiceret til behandling af vedvarende neutropeni (ANC ≤ 1, 0 x 109/ l) hos patienter med fremskreden hiv- infektion for at reducere risikoen for bakterielle infektions, når andre behandlingsmuligheder ved neutropeni ikke er hensigtsmæssige..
Ratiograstim is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/ l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.